Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
Edi Widjajanto
Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Malang
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
NRAS, RUNX1 POLYMORPHISM AND CHROMOSOME 5 DELETION [DEL(5q)] AS MYELODYSPLASTIC SYNDROME RELATED ACUTE MYELOID LEUKEMIA PREDICTOR IN SURABAYA Mulya Dinata; Siprianus Ugroseno Yudho Bintoro; Edi Widjajanto; Windhu Purnomo
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 32 No. 2 (2026)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v32i2.2828

Abstract

Myelodysplastic syndrome (MDS) is a well-organized hematopoiesis (Apoptosis) that becomes dysplastic and ineffective (Anti-Apoptosis). It is characterized by a slight increase in the number of immature blood cells (Blasts) in bone marrow, which can develop into acute myeloid leukemia (AML; MDS-related AML). In this study, Researchers sought to determine whether abnormalities in NRAS, RUNX1, and chromosome 5 deletion (del[5q]) can be used as predictors of MDS-related AML. This study employed an analytical cross-sectional design involving a total of 36 samples, consisting of 31 confirmed AML cases and 5 clinically diagnosed MDS cases. The occurrence of NRAS, RUNX1 mutations, and deletion of chromosome 5 deletion (del[5q]) was examined using polymerase chain reaction (PCR) and chromogenic in situ hybridization (CISH). Our analysis demonstrates that NRAS and RUNX1 mutations, alongside chromosome 5q deletion (del[5q]), are significantly associated with the progression of MDS-related AML.  Statistical evaluation via ROC curve showed an AUC of 0.765 (95% CI, p=0.036), demonstrating the model’s significant performance in predicting disease progression. Above or below the cut-off value (0.7825584010 ) indicates strong or weak predictions of MDS-related AML based on the ROC curve. Mutation of RUNX1 coefficient B-1.694 and exponent B 0.184 decreased the progression to MDS-related AML, while NRAS mutation coefficient 2.446 and exponent B 11.53 increased the progression of MDS-related AML. Normal cytogenetics of Chromosome 5, RUNX1 mutation inhibits progression, while NRAS mutation increases progression of MDS-related AML. NRAS and RUNX1 mutations, as well as Chromosome 5 deletion (del[5q]) can be strong predictors of progression to MDS-related AML in Surabaya.
Co-Authors Mulya Dinata Siprianus Ugroseno Yudho Bintoro Windhu Purnomo